Clinical trial specialist Ergomed Plc (LON:ERGO) lifted 2016 revenues by nearly a third as its drug monitoring business continued to power ahead.
Pharmavigilance checks on the performance of drugs once they have been launched and boosted by the acquisition of Pharmainvent in November, sales on this side of the business rose by 63%.
Revenues overall rose by 30% to 39.2mln though profits took a dip as Ergomed included the R&D expenditure (£1mln) of new subsidiary Haemostatix for the first time.
Haemostatix is different from the normal model of the company as Ergomed is carrying out the development itself, whereas previously it has taken stakes in drugs where it is running a clinical trial.
It has just started a phase IIB study for surgical bleeding drug Peprostat, while one of its co-development portfolio, insomnia drug Ferrer, released encouraging phase II results in February.
Profits in 2016 dropped to £326,000 (£2.07mln), reflecting the R&D and £761,000 of other one-offs.
Shares rose 4% to 204p.
--updates for share price--